PMID- 9518162
OWN - NLM
STAT- MEDLINE
DCOM- 19980325
LR  - 20190831
IS  - 1387-2273 (Print)
IS  - 1387-2273 (Linking)
VI  - 704
IP  - 1-2
DP  - 1997 Dec 19
TI  - Simultaneous determination of O6-benzylguanine and 8-oxo-O6-benzylguanine in 
      human plasma by reversed-phase high-performance liquid chromatography.
PG  - 289-98
AB  - A high-performance liquid chromatographic assay for the quantification of 
      O6-benzylguanine (O6BG) in human plasma was modified to include the metabolite, 
      O6-benzyl-8-oxo-guanine (8-oxo-O6BG). O6-(p-Chlorobenzyl)guanine was used as the 
      internal standard. Plasma samples were extracted with ethyl acetate and 
      chromatographed on a C18 base-deactivated reversed-phase column. Separation was 
      accomplished by gradient elution with mobile phases consisting of acetonitrile 
      and phosphate buffer, pH 3.60. Eluted compounds were observed with diode array 
      detection at 288 nm (O6BG) and 292 nm (8-oxo-O6BG). Standard curves were linear 
      from 12.5 ng/ml to 1000 ng/ml, with an average regression coefficient of 0.999 
      (n=5) for both compounds. The lowest limit of quantitation was 25 ng/ml, with a 
      signal-to-noise ratio of 8:1. The within-day relative standard deviations for 
      O6BG quality control samples (n=18) with concentrations of 735 ng/ml, 305 ng/ml 
      and 38 ng/ml were 2.4%, 4.2% and 5.3%, respectively. The within-day relative 
      standard deviations for 8-oxo-O6BG quality control samples (n=18) at 
      concentrations of 735 ng/ml, 420 ng/ml and 42 ng/ml were 2.2%, 4.0% and 7.1%, 
      respectively. The day-to-day relative standard deviations for the same control 
      specimens were 3.1%, 4.8% and 7.1% for O6BG, respectively, and 2.3%, 4.7% and 
      11.0% for 8-oxo-O6BG, respectively. This method was applied to plasma samples 
      obtained from patients in a clinical trial of O6-benzylguanine. 
      O6-Benzyl-8-oxo-guanine was identified in patient plasma specimens by liquid 
      chromatography-electrospray mass spectrometry by comparison with spectral data 
      acquired from reference material.
FAU - Stefan, T L
AU  - Stefan TL
AD  - Department of Pharmacology, Case Western Reserve University, Cleveland, OH 44106, 
      USA.
FAU - Ingalls, S T
AU  - Ingalls ST
FAU - Minkler, P E
AU  - Minkler PE
FAU - Willson, J K
AU  - Willson JK
FAU - Gerson, S L
AU  - Gerson SL
FAU - Spiro, T P
AU  - Spiro TP
FAU - Hoppel, C L
AU  - Hoppel CL
LA  - eng
GR  - P01 CA51183/CA/NCI NIH HHS/United States
GR  - P30 CA43703/CA/NCI NIH HHS/United States
GR  - UO1 CA62502/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - J Chromatogr B Biomed Sci Appl
JT  - Journal of chromatography. B, Biomedical sciences and applications
JID - 9714109
RN  - 0 (8-oxo-O(6)-benzylguanine)
RN  - 0 (Antineoplastic Agents)
RN  - 01KC87F8FE (O(6)-benzylguanine)
RN  - 5Z93L87A1R (Guanine)
SB  - IM
MH  - Antineoplastic Agents/*blood
MH  - Chromatography, High Pressure Liquid/*methods
MH  - Guanine/*analogs & derivatives/blood/metabolism
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Quality Control
MH  - Sensitivity and Specificity
EDAT- 1998/03/28 00:00
MHDA- 1998/03/28 00:01
CRDT- 1998/03/28 00:00
PHST- 1998/03/28 00:00 [pubmed]
PHST- 1998/03/28 00:01 [medline]
PHST- 1998/03/28 00:00 [entrez]
AID - 10.1016/s0378-4347(97)00446-5 [doi]
PST - ppublish
SO  - J Chromatogr B Biomed Sci Appl. 1997 Dec 19;704(1-2):289-98. doi: 
      10.1016/s0378-4347(97)00446-5.